Exploration into Plasma Hsa_circ_0052184 as a New Biomarker of Colorectal Cancer Prognosis
DOI: https://doi.org/10.2147/PGPM.S413451
2023-06-12
Pharmacogenomics and Personalized Medicine
Abstract:Enqi Zheng, Deshuang Xiao Hernia Vascular Surgery, The First People's Hospital of Wenling, Wenling, Zhejiang, People's Republic of China Correspondence: Deshuang Xiao, Hernia Vascular Surgery, The First People's Hospital of Wenling, No. 333 Chuan'an South Road, Chengxi Street, Wenling, 317599, Zhejiang, People's Republic of China, Tel +86-057689668595, Email Background: Circular RNAs (circRNAs) are strong modulators of tumor pathology. Herein, our goal was to examine the plasma hsa_circ_0052184 content among colorectal cancer (CRC) patients, and assess its association with patient clinicopathological profile and diagnostic values. Methods: Overall, we collected 228 presurgical CRC and 146 normal plasma samples from The First People's Hospital of Wenling. Circulating hsa_circ_0052184 levels were assessed via qRT-PCR, and the diagnostic prediction was conducted with the receiver operating characteristic (ROC) curve. Results: Relative to healthy controls, CRC patients exhibited markedly enhanced circulating hsa_circ_0052184 levels, which were closely correlated with advanced stage of disease and worse outcome. Based on our uni- (UA) and multivariate assessments (MA), elevated hsa_circ_0052184 levels were a stand-alone predictor of poor prognosis. The ROC curve depicted an area under the curve (AUC) for CRC diagnosis to be 0.9072. Conclusion: Circulating hsa_circ_0052184 is a potential bioindicator of CRC outcome. Keywords: hsa_circ_0052184, diagnostic biomarker, colorectal cancer Colorectal cancer (CRC) is the third leading form of global malignancy, and is the second contributor to cancer-associated deaths. 1 Based on reports from the Global Cancer Statistics 2020, the year 2020 alone brought over 1.9 million new CRC incidences, with 935,000 associated fatalities from around the world. This accounted for approximately 10% of all cancer cases and associated mortalities. 2 Common CRC therapies include surgery, accompanied by radio-, chemo-, or targeted therapies. Notably, older patients with T4 CRC were more prone to severe postoperative complications, but age did not impact survival outcomes. For this reason, older patients should not be denied surgery for T4 CRC based on age alone. 3 Employing endogenous biomarkers in cancer diagnosis, like in CRC, holds great significance. 4,5 More recently, liquid biopsy is increasingly employed as a non-invasive approach to disease diagnosis in hospitals. 6 Moreover, with advancements in high-throughput omics (for example, genomics, proteomics, and metabolomics) as well as development of novel identification protocols, scientists have uncovered several novel tumor biomarkers, particularly, those involving noncoding RNAs (ncRNAs). 7–9 In contrast, linear RNAs are relatively unstable in vitro, and degrade easily, which restricts its clinical usage. Circular RNAs (circRNAs) are a newly discovered group of ncRNAs, with a characteristic stable and circular configuration. 10–12 Several reports suggest circRNAs as potential disease bioindicators owing to their tissue- and disease stage-specific expression profile. 13,14 Their primary action is gene regulation via modulation of micro RNAs (miRNAs) 15 and protein. 14 Owing to their contribution to several cell transduction networks, circRNAs may be employed as diagnostic and/or prognostic agents in multiple cancers, including CRC. 16,17 Among its unique characteristics is its covalent cyclic configuration, which allows it to escape digestion by exonucleases. Moreover, its relatively stable nature, especially in body fluids (namely, blood, urine, and saliva) it allows it to be a superior disease biomarker, compared to linear RNAs. 18 Human hsa_circ_0052184 is a newly discovered circRNA harboring 221bp nt in spliced sequence length. Its gene resides on chr19:55603809–55604030, and its gene symbol is PPP1R12C. Herein, we attempted to assess the diagnostic power, as well as the tissue and plasma sensitivity of hsa_circ_0052184 in early-stage CRC diagnosis. Overall, we collected 228 presurgical CRC and 146 normal plasma samples from The First People's Hospital of Wenling. The following patients were included in our analysis: those (a) with primary CRC diagnosis, as evidenced by pathological examination; (b) between 18–80 years of age; (c) with complete tumor and survival information; and (d) with no neoadjuvant treatment prior to operation. Upon collection, samples were maintained at −80°C until further analysis. The research strategy was formulated in accordance with the Declaration of Helsinki. This research received ethical approval (KY-2023-1004-01) from the The First People's Hospital of Wenling, and received informed consent f -Abstract Truncated-
pharmacology & pharmacy